RECRUITING Phase 3 ClinicalTrials.gov

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Sponsor: Pfizer • ClinicalTrials.gov ID: NCT06807281

Registry updated: 2026-10-13

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.

Interventions

Abrocitinib (Drug)
Abrocitinib administered as liquid oral suspension.

Eligibility criteria

Inclusion Criteria for the Extension Cohort: 1\. Participants who have completed the treatment phase of the qualifying parent study (age 2 to \<12 years old). • No contraception methods are required for male participants. Female participants must not be pregnant or breastfeeding and, if the participant is of child-bearing potential, must use a highly effective form of contraception (i.e., abstinence) during the study intervention period and for at least 28 days after the last dose of study intervention. Inclusion Criteria for the De Novo Cohort: Age 1. Children aged 6 to \<12 years at the time of informed consent/assent. • No contraception methods are required for male participants. Disease Characteristics: 2. Participants who meet all of the following AD criteria: * A documented diagnosis of chronic AD for at least 6 months prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria; and * A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and * Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy. Other Inclusion Criteria: 3. Body weight ≥15 kg Exclusion Criteria for the Extension Cohort: Medical Conditions: 1. Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. If the participant has SDQ total score ≥17, the investigator should exclude the child or refer them to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents. Prior/Concomitant Therapy: 2. Required use of any prohibited concomitant treatments outlined in Section 6.9.3 and Appendix 9 of study protocol. 3. Required vaccination with live attenuated vaccines during study treatment and for 6 weeks after discontinuing study treatment. Diagnostic Assessments: 4. Ongoing adverse event in the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern OR the participant is currently triggering safety monitoring criteria. 5. Discontinued from treatment early in the parent studies OR triggered a discontinuation criterion at any point during the parent studies OR meets exclusion criteria from the parent studies which in the opinion of the investigator, or sponsor, is an ongoing safety concern. Exclusion Criteria for the De Novo Cohort Medical Conditions: 1. Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents. 2. Have any of the following medical conditions: * Infections: * Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (baseline) or have superficial skin infections within 1 week of Day 1. * History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1. * Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster. * Infection with HIV, hepatitis B, and/or hepatitis C * Evidence of active TB or inadequately treated latent TB. * Skin Conditions: \- Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment. * Other Conditions: * Documented history of skeletal dysplasia. * Documented history of retinal detachment. * History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction. * Prior history of leukemia, lymphoma, sarcoma or any other malignancy. * Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency. * Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study. Prior/Concomitant Therapy: 3. Prior treatment with a systemic JAK inhibitor for AD. 4. Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention. 5. Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes and strong inducers of CYP2C9 enzymes is not allowed in the study. Prior/Concurrent Clinical Study Experience: 6. Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1. Diagnostic Assessments: 7. Hepatic and/or renal and/or hematological abnormalities defined as: * AST \>2 x ULN * Hemoglobin \<10 g/dL * ALT \>2 x ULN * ANC \<1000/mm3 * Total bilirubin ≥1.5 x ULN * ALC \<500/mm3 * eGFR \<60 mL/min/1.73 m2 * Platelets \<150,000 /mm3 Other Exclusion Criteria: 8. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

Conditions

Atopic Dermatitis

Locations

Cahaba Dermatology & Skin Health Center — Birmingham, Alabama, United States
Arkansas Research Trials — North Little Rock, Arkansas, United States
Investigational Drug Service - Rady Childrens Hospital-San Diego — San Diego, California, United States
University of California, San Diego/ Rady Children's Hospital - San Diego — San Diego, California, United States
Solutions Through Advanced Research — Jacksonville, Florida, United States
Ada West Research - Meridian — Meridian, Idaho, United States
Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana, United States
Saint Louis University — St Louis, Missouri, United States
Medical University of South Carolina - South Carolina Translational Research Nexus Clinic — Charleston, South Carolina, United States
Tribe Clinical Research, LLC — Greenville, South Carolina, United States
Texas Dermatology and Laser Specialists — San Antonio, Texas, United States
Beijing Children's hospital, Capital Medical University — Beijing, Beijing Municipality, China
Shenzhen Children's Hospital — Shenzhen, Guangdong, China
Hunan Children's Hospital — Changsha, Hunan, China
Dermatology Hospital of Jiangxi Province — Nanchang, Jiangxi, China
Hangzhou Third People's Hospital — Hangzhou, Zhejiang, China
Shanghai Children's Hospital — Shanghai, China
Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine — Shanghai, China
Pécsi Tudományegyetem Klinikai Központ — Pécs, Baranya, Hungary
Trial Pharma Kft. — Békéscsaba, Bekes County, Hungary
Clinexpert Kft. — Budapest, Pest County, Hungary
Queen's square Medical Facilities Queen's square Dermatology and Allergology — Yokohama, Kanagawa, Japan
Dermatology and Ophthalmology Kume Clinic — Sakai, Osaka, Japan
Sasamoto Children's Clinic — Setagaya-ku, Tokyo, Japan
Fukuoka National Hospital — Fukuoka, Japan
Saruta Dermatology Clinic — Fukuoka, Japan
Hospital Infantil de Mexico Federico Gomez — Mexico City, Mexico City, Mexico
Eukarya Pharmasite S.C. — Monterrey, Nuevo León, Mexico
Arké SMO S.A de C.V — Veracruz, Veracruz Ignacio de LA Llave, Mexico
Servicios Hospitalarios de Mexico S.A. DE C.V. — Chihuahua City, Mexico
LUXDERM Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska — Lublin, Lublin Voivodeship, Poland
Centrum Medyczne Evimed — Warsaw, Masovian Voivodeship, Poland
DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gebska — Chorzów, Silesian Voivodeship, Poland
Centrum Medyczne Angelius Provita — Katowice, Silesian Voivodeship, Poland
Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak — Lodz, Łódź Voivodeship, Poland
Dermedic Jacek Zdybski — Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, Poland
CHUS - Hospital Clinico Universitario — Santiago de Compostela, A Coruña [LA Coruña], Spain
Hospital General de Granollers — Granollers, Barcelona, Spain
Hospital Universitario Miguel Servet — Zaragoza, Spain

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment